Anxiety Disorders And Depression Treatment Market Analysis By Product (Antidepressant Drugs, SSRIs, SNRIs, Benzodiazepines, Devices And Therapy, TNS, DBS, VBS), By Indication (MDD, OCD, Phobia), And Segment Forecasts, 2014 - 2025

  • ID: 4031956
  • Report
  • 100 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lily & Co
  • Forest Laboratories, Inc
  • GlaxoSmithKline
  • H. Lundbeck A/S
  • Johnson & Johnson
  • MORE
The global anxiety disorders and depression treatment market is expected to reach a value of USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated to drive the market growth in the coming years. Increasing adoption of devices and psychotherapies has resulted in the declining demand for antidepressants in the recent years.

The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.

Further key findings from the study suggest:

Presently, the antidepressant drugs segment holds the largest revenue share. However, due to the rising occurrence of adverse events associated with these therapeutics, this segment’s growth is expected to wane

Patent expiration of branded medicines and introduction of generic biosimilars, which are cost effective, are responsible for the shrinking market of antidepressants

On the other hand, introduction of new medicines, such as Duloxetine, Fetzima, and Brintellix, are predicted to fuel the demand for therapeutics in the coming years

Furthermore, the personalized therapies and devices segment is expected to register the fastest growth owing to its growing adoption by healthcare professionals as they exert fewer side effects as compared to drugs

Cognitive behavioral therapy held the majority share in 2015 and is expected to register substantial growth in the coming years owing to the shifting preference of healthcare professionals toward this segment

Transcranial Magnetic Stimulation (TMS) is predicted to witness lucrative growth due to the introduction of technologically advanced devices such as MagVita TMS Therapy System by MagVenture in July 2015 and Brainsway Deep TMS in January 2013

North American regional segment for anxiety disorders and depression treatment reached a saturation level owing to the availability of several medicines and the high prevalence of depressive disorders in this region

Pfizer, Inc.; Eli Lilly and Company;GlaxoSmithKline plc; AstraZeneca; and H. Lundbeck A/S captured a sizable share in 2015 and accounted for more than 60% of the antidepressant drugs vertical

The revenue captured by antidepressants is expected to decrease with generics dominating the market during the forecast period
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lily & Co
  • Forest Laboratories, Inc
  • GlaxoSmithKline
  • H. Lundbeck A/S
  • Johnson & Johnson
  • MORE
1 Research Methodology & Scope
1.1 Region Wise Market Calculation
1.1.1 Region Wise Market: Base Estimates
1.1.2 Global Market: CAGR Calculation
1.2 Region based segment share calculation
1.3 List of Secondary Sources

2 Executive Summary
2.1 Market Snapshot

3 Anxiety Disorder And Depression Treatment Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis
3.1.1.1 Increasing prevalence of depression
3.1.1.2 Emergence of novel biologics
3.1.1.3 Increasing awareness level
3.1.2 Market Restraint Analysis
3.1.2.1 Patent expiration of branded drugs
3.2 Penetration & growth prospect mapping
3.3 Anxiety Disorders and Depression Treatment - PESTLE Analysis
3.4 Industry Analysis - Porter’s

4 Market Categorization 1: Product Estimates & Trend Analysis
4.1 Anxiety Disorders and Depression Treatment Market: Product Movement Analysis
4.2 Antidepressant Drugs
4.2.1 Antidepressant drugs market, 2014 - 2025 (USD Million)
4.2.2 Selective Serotonin Reuptake Inhibitors (SSRIs)
4.2.2.1 SSRIs market, 2014 - 2025 (USD Million)
4.2.3 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
4.2.3.1 SNRIs market, 2014 - 2025 (USD Million)
4.2.4 Tricyclic Antidepressants (TCAs)
4.2.4.1 TCAs market, 2014 - 2025 (USD Million)
4.2.5 Monoamine Oxidase inhibitors (MAOIs)
4.2.5.1 MAOIs market, 2014 - 2025 (USD Million)
4.2.6 Atypical Antipsychotics
4.2.6.1 Atypical antipsychotics market, 2014 - 2025 (USD Million)
4.2.7 Benzodiazepines
4.2.7.1 Benzodiazepines market, 2014 - 2025 (USD Million)
4.2.8 Anticonvulsants
4.2.8.1 Anticonvulsants market, 2014 - 2025 (USD Million)
4.2.9 Beta-Blockers
4.2.9.1 Beta-Blockers market, 2014 - 2025 (USD Million)
4.2.10 Others
4.2.10.1 Others market, 2014 - 2025 (USD Million)
4.3 Therapy & Devices
4.3.1 Therapy & devices market, 2014 - 2025 (USD Million)
4.3.2 Fisher-Wallace stimulator
4.3.2.1 Fisher-Wallace stimulator market, 2014 - 2025 (USD Million)
4.3.3 Transcranial Magnetic Stimulation (TMS)
4.3.3.1 TMS market, 2014 - 2025 (USD Million)
4.3.4 Deep Brain Stimulation (DBS)
4.3.4.1 DBS market, 2014 - 2025 (USD Million)
4.3.5 Vagus nerve stimulation (VNS)
4.3.5.1 VNS market, 2014 - 2025 (USD Million)
4.3.6 Electroconvulsive Therapy (ECT)
4.3.6.1 ECT market, 2014 - 2025 (USD Million)
4.3.7 Cognitive Behaviour Therapy (CBT)
4.3.7.1 CBT market, 2014 - 2025 (USD Million)
4.3.8 Others
4.3.8.1 Others market, 2014 - 2025 (USD Million)

5 Market Categorization 2: Indication Estimates & Trend Analysis
5.1 Anxiety disorders and depression treatment market: indication movement analysis
5.2 Major Depressive Disorder (MDD)
5.2.1 MDD market, 2014 - 2025 (USD Million)
5.3 Obsessive-Compulsive Disorder (OCD)
5.3.1 OCD market, 2014 - 2025 (USD Million)
5.4 Phobia
5.4.1 Phobia market, 2014 - 2025 (USD Million)
5.5 Others
5.5.1 Others market, 2014 - 2025 (USD Million)

6 Market Categorization 3: Regional Estimates & Trend Analysis, by Product Type and Indication
6.1 Anxiety Disorders and Depression Treatment market share by region, 2015 & 2025
6.2 North America
6.2.1 North America Anxiety Disorders and Depression Treatment market, 2014 - 2025 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. Anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
6.2.3 Canada
6.2.3.1 Canada anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Europe anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
6.3.2 UK
6.3.2.1 UK anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
6.3.3 Germany
6.3.3.1 Germany anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
6.4.2 Japan
6.4.2.1 Japan anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
6.4.3 China
6.4.3.1 China anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
6.4.4 India
6.4.4.1 India anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
6.6 MEA
6.6.1 MEA anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)

7 Competitive Landscape
7.1 Strategy framework
7.2 Market participation categorization
7.3 Company Profiles
7.3.1 Pfizer Inc,
7.3.1.1 Company Overview
7.3.1.2 Financial Performance
7.3.1.3 Product Benchmarking
7.3.1.4 Strategic Initiatives
7.3.2 GlaxoSmithKline
7.3.2.1 Company Overview
7.3.2.2 Financial Performance
7.3.2.3 Product Benchmarking
7.3.3 Merck & Co. Inc
7.3.3.1 Company Overview
7.3.3.2 Financial Performance
7.3.3.3 Product Benchmarking
7.3.3.4 Strategic Initiatives
7.3.4 AstraZeneca
7.3.4.1 Company Overview
7.3.4.2 Financial Performance
7.3.4.3 Product Benchmarking
7.3.4.4 Strategic Initiatives
7.3.5 Eli Lily & Co
7.3.5.1 Company Overview
7.3.5.2 Financial Performance
7.3.5.3 Product Benchmarking
7.3.5.4 Strategic Initiatives
7.3.6 Johnson & Johnson
7.3.6.1 Company Overview
7.3.6.2 Financial Performance
7.3.6.3 Product Benchmarking
7.3.6.4 Strategic Initiatives
7.3.7 Forest Laboratories, Inc
7.3.7.1 Company Overview
7.3.7.2 Financial Performance
7.3.7.3 Product Benchmarking
7.3.7.4 Strategic Initiatives
7.3.8 Sanofi-Aventis
7.3.8.1 Company Overview
7.3.8.2 Financial Performance
7.3.8.3 Product Benchmarking
7.3.8.4 Strategic Initiatives
7.3.9 H. Lundbeck A/S
7.3.9.1 Company Overview
7.3.9.2 Financial Performance
7.3.9.3 Product Benchmarking
7.3.9.4 Strategic Initiatives
7.3.10 Bristol-Myers Squibb Company
7.3.10.1 Company Overview
7.3.10.2 Financial Performance
7.3.10.3 Product Benchmarking
7.3.10.4 Strategic Initiatives

List of Tables

Table 1 Country share estimation
Table 2 Pipeline drugs for anxiety & depression treatment
Table 3 North America anxiety disorders and depression treatment market, by product, 2014 - 2025 (USD Million)
Table 4 North America antidepressants market, by drug class, 2014 - 2025 (USD Million)
Table 5 North America devices & therapy market, by type, 2014 - 2025 (USD Million)
Table 6 North America anxiety disorders and depression treatment market, by indication, 2014 - 2025 (USD Million)
Table 7 U.S. anxiety disorders and depression treatment market, by product, 2014 - 2025 (USD Million)
Table 8 U.S. antidepressants market, by drug class, 2014 - 2025 (USD Million)
Table 9 U.S. devices & therapy market, by type, 2014 - 2025 (USD Million)
Table 10 U.S. anxiety disorders and depression treatment market, by indication, 2014 - 2025 (USD Million)
Table 11 Canada anxiety disorders and depression treatment market, by product, 2014 - 2025 (USD Million)
Table 12 Canada antidepressants market, by drug class, 2014 - 2025 (USD Million)
Table 13 Canada devices & therapy market, by type, 2014 - 2025 (USD Million)
Table 14 Canada anxiety disorders and depression treatment market, by indication, 2014 - 2025 (USD Million)
Table 15 Europe anxiety disorders and depression treatment market, by product, 2014 - 2025 (USD Million)
Table 16 Europe antidepressants market, by drug class, 2014 - 2025 (USD Million)
Table 17 Europe devices & therapy market, by type, 2014 - 2025 (USD Million)
Table 18 Europe anxiety disorders and depression treatment market, by indication, 2014 - 2025 (USD Million)
Table 19 UK anxiety disorders and depression treatment market, by product, 2014 - 2025 (USD Million)
Table 20 UK antidepressants market, by drug class, 2014 - 2025 (USD Million)
Table 21 UK devices & therapy market, by type, 2014 - 2025 (USD Million)
Table 22 UK anxiety disorders and depression treatment market, by indication, 2014 - 2025 (USD Million)
Table 23 Germany anxiety disorders and depression treatment market, by product, 2014 - 2025 (USD Million)
Table 24 Germany antidepressants market, by drug class, 2014 - 2025 (USD Million)
Table 25 Germany devices & therapy market, by type, 2014 - 2025 (USD Million)
Table 26 Germany anxiety disorders and depression treatment market, by indication, 2014 - 2025 (USD Million)
Table 27 Asia Pacific anxiety disorders and depression treatment market, by product, 2014 - 2025 (USD Million)
Table 28 Asia Pacific antidepressants market, by drug class, 2014 - 2025 (USD Million)
Table 29 Asia Pacific devices & therapy market, by type, 2014 - 2025 (USD Million)
Table 30 Asia Pacific anxiety disorders and depression treatment market, by indication, 2014 - 2025 (USD Million)
Table 31 Japan anxiety disorders and depression treatment market, by product, 2014 - 2025 (USD Million)
Table 32 Japan antidepressants market, by drug class, 2014 - 2025 (USD Million)
Table 33 Japan devices & therapy market, by type, 2014 - 2025 (USD Million)
Table 34 Japan anxiety disorders and depression treatment market, by indication, 2014 - 2025 (USD Million)
Table 35 China anxiety disorders and depression treatment market, by product, 2014 - 2025 (USD Million)
Table 36 China antidepressants market, by drug class, 2014 - 2025 (USD Million)
Table 37 China devices & therapy market, by type, 2014 - 2025 (USD Million)
Table 38 China anxiety disorders and depression treatment market, by indication, 2014 - 2025 (USD Million)
Table 39 India anxiety disorders and depression treatment market, by product, 2014 - 2025 (USD Million)
Table 40 India antidepressants market, by drug class, 2014 - 2025 (USD Million)
Table 41 India devices & therapy market, by type, 2014 - 2025 (USD Million)
Table 42 India anxiety disorders and depression treatment market, by indication, 2014 - 2025 (USD Million)
Table 43 Latin America anxiety disorders and depression treatment market, by product, 2014 - 2025 (USD Million)
Table 44 Latin America antidepressants market, by drug class, 2014 - 2025 (USD Million)
Table 45 Latin America devices & therapy market, by type, 2014 - 2025 (USD Million)
Table 46 Latin America anxiety disorders and depression treatment market, by indication, 2014 - 2025 (USD Million)
Table 47 Brazil anxiety disorders and depression treatment market, by product, 2014 - 2025 (USD Million)
Table 48 Brazil, antidepressants market, by drug class, 2014 - 2025 (USD Million)
Table 49 Brazil devices & therapy market, by type, 2014 - 2025 (USD Million)
Table 50 Brazil anxiety disorders and depression treatment market, by indication, 2014 - 2025 (USD Million)
Table 51 Mexico anxiety disorders and depression treatment market, by product, 2014 - 2025 (USD Million)
Table 52 Mexico antidepressants market, by drug class, 2014 - 2025 (USD Million)
Table 53 Mexico devices & therapy market, by type, 2014 - 2025 (USD Million)
Table 54 Mexico anxiety disorders and depression treatment market, by indication, 2014 - 2025 (USD Million)
Table 55 MEA anxiety disorders and depression treatment market, by product, 2014 - 2025 (USD Million)
Table 56 MEA antidepressants market, by drug class, 2014 - 2025 (USD Million)
Table 57 MEA devices & therapy market, by type, 2014 - 2025 (USD Million)
Table 58 MEA anxiety disorders and depression treatment market, by indication, 2014 - 2025 (USD Million)
Table 59 South Africa anxiety disorders and depression treatment market, by product, 2014 - 2025 (USD Million)
Table 60 South Africa antidepressants market, by drug class, 2014 - 2025 (USD Million)
Table 61 South Africa devices & therapy market, by type, 2014 - 2025 (USD Million)
Table 62 South Africa anxiety disorders and depression treatment market, by indication, 2014 - 2025 (USD Million)

List of Figures

Figure 1 Market summary
Figure 2 Market trends & outlook
Figure 3 Market segmentation & scope
Figure 4 Market driver relevance analysis (Current & future impact)
Figure 5 Market restraint relevance analysis (Current & future impact)
Figure 6 Penetration & growth prospect mapping
Figure 7 Anxiety Disorders and Depression Treatment PESTLE Analysis
Figure 8 Porter’s Five Forces Analysis
Figure 9 Anxiety disorders and depression treatment market product outlook key takeaways
Figure 10 Anxiety disorders and depression treatment market: product movement analysis
Figure 11 Antidepressant drugs market, 2014 - 2025 (USD Million)
Figure 12 SSRIs market, 2014 - 2025 (USD Million)
Figure 13 SNRIs market, 2014 - 2025 (USD Million)
Figure 14 TCAs market, 2014 - 2025 (USD Million)
Figure 15 MAOIs market, 2014 - 2025 (USD Million)
Figure 16 Atypical antipsychotics market, 2014 - 2025 (USD Million)
Figure 17 Benzodiazepines market, 2014 - 2025 (USD Million)
Figure 18 Anticonvulsants market, 2014 - 2025 (USD Million)
Figure 19 Global Beta-Blockersmarket, 2014 - 2025 (USD Million)
Figure 20 Global others market, 2014 - 2025 (USD Million)
Figure 21 Therapy & devices market, 2014 - 2025 (USD Million)
Figure 22 Global fisher-wallace stimulator market, 2014 - 2025 (USD Million)
Figure 23 Global TMS market, 2014 - 2025 (USD Million)
Figure 24 Global DBS market, 2014 - 2025 (USD Million)
Figure 25 Global VNS market, 2014 - 2025 (USD Million)
Figure 26 Global ECT market, 2014 - 2025 (USD Million)
Figure 27 Global CBT market, 2014 - 2025 (USD Million)
Figure 28 Global others market, 2014 - 2025 (USD Million)
Figure 29 Anxiety disorders and depression treatment market indication outlook key takeaways
Figure 30 Anxiety Disorders and Depression Treatment market: indication movement analysis
Figure 31 MDD market, 2014 - 2025 (USD Million)
Figure 32 OCD market, 2014 - 2025 (USD Million)
Figure 33 Phobia market, 2014 - 2025 (USD Million)
Figure 34 Others market, 2014 - 2025 (USD Million)
Figure 35 Regional market place: Key takeaways
Figure 36 Regional outlook, 2015 & 2025
Figure 37 North America anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
Figure 38 U.S. anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
Figure 39 Canada anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
Figure 40 Europe anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
Figure 41 UK Anxiety Disorders and Depression Treatment market, 2014 - 2025 (USD Million)
Figure 42 Germany anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
Figure 43 Asia Pacific anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
Figure 44 Japan anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
Figure 45 China anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
Figure 46 India anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
Figure 47 Latin America anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
Figure 48 Brazil anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
Figure 49 Mexico anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
Figure 50 MEA anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
Figure 51 South Africa anxiety disorders and depression treatment market, 2014 - 2025 (USD Million)
Figure 52 Strategy framework
Figure 53 Participant categorization
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Pfizer Inc,
  • GlaxoSmithKline
  • Merck & Co. Inc
  • AstraZeneca
  • Eli Lily & Co
  • Johnson & Johnson
  • Forest Laboratories, Inc
  • Sanofi-Aventis
  • H. Lundbeck A/S
  • Bristol-Myers Squibb Company
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll